127 related articles for article (PubMed ID: 9468551)
1. Role of urokinase-type plasminogen activator in local immunotherapy.
Takeda T; Ito Y; Wakasugi E; Kobayashi T; Monden M
Oncol Rep; 1998; 5(2):329-33. PubMed ID: 9468551
[TBL] [Abstract][Full Text] [Related]
2. [Effect of intratumoral injection of the mixture of OK-432 and fibrinogen (OK/fbg) on gastric cancer].
Takeda T; Wakasugi T; Katsumoto Y; Sakita I; Nagaoka H; Morimoto H; Tsujinaka T; Monden T; Shiozaki H; Shimano T
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1458-60. PubMed ID: 1530293
[TBL] [Abstract][Full Text] [Related]
3. [Intratumoral injection of OK-432 in conjunction with fibrinogen greatly enhances antitumor effect on colorectal carcinomas].
Monden T; Morimoto H; Murotani M; Yagyu T; Nagaoka H; Shimano T; Mori T
Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):31-6. PubMed ID: 1707498
[TBL] [Abstract][Full Text] [Related]
4. The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages.
Takeda T; Kobayashi T; Monden T; Katsumoto Y; Ito Y; Wakasugi E; Wakasugi T; Tomita N; Shimano T; Mori T
Biotherapy; 1993; 7(1):47-54. PubMed ID: 8068483
[TBL] [Abstract][Full Text] [Related]
5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
6. [Local immunotherapy of breast cancer: a case of advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2].
Fujimori M; Sugenoya A; Kobayashi S; Masuda H; Komatsu M; Takahashi S; Shimizu T; Tsuchiya S; Iida F
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2760-3. PubMed ID: 2551219
[TBL] [Abstract][Full Text] [Related]
7. [Locoregional injection of OK-432/fibrinogen/thrombin for unresectable metastatic liver tumors].
Yoshida T; Osato H; Sakon M; Monden T; Amano M; Aoki T; Kishimoto S; Umeshita K; Dono K; Gotoh M; Monden M
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1575-7. PubMed ID: 8854809
[TBL] [Abstract][Full Text] [Related]
8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
9. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
10. Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Amano M; Sekimoto M; Monden T; Tomita N; Ohue M; Haba A; Sakita I; Tamaki Y; Monden M
Dis Colon Rectum; 2000 Mar; 43(3):402-7. PubMed ID: 10733124
[TBL] [Abstract][Full Text] [Related]
11. [A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin].
Takekuni K; Sakon M; Kishimoto S; Amano M; Sekimoto M; Aoki T; Oosato H; Dohno K; Umeshita K; Gotoh M; Monden T; Monden M
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1621-3. PubMed ID: 8854822
[TBL] [Abstract][Full Text] [Related]
12. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
15. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection].
Hosokawa T
Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533
[TBL] [Abstract][Full Text] [Related]
17. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
19. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
20. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Inuzuka K; Ogata Y; Nagase H; Shirouzu K
J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
